Marc Tessier-Lavigne - Jun 7, 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Jun 7, 2021
Transactions value $
-$4,874,248
Form type
4
Date filed
6/8/2021, 05:10 PM
Previous filing
Jun 4, 2021
Next filing
Sep 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $707K +39.3K +1.54% $18.00 2.58M Jun 7, 2021 Direct F1
transaction DNLI Common Stock Options Exercise $527K +27.8K +1.08% $18.92 2.61M Jun 7, 2021 Direct F1
transaction DNLI Common Stock Options Exercise $531K +27.2K +1.04% $19.50 2.64M Jun 7, 2021 Direct F1
transaction DNLI Common Stock Sale -$6.59M -93.7K -3.55% $70.35 2.55M Jun 7, 2021 Direct F1, F2, F3
transaction DNLI Common Stock Sale -$49.7K -700 -0.03% $71.06 2.54M Jun 7, 2021 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -39.3K -83.33% $0.00 7.86K Jun 7, 2021 Common Stock 39.3K $18.00 Direct F5
transaction DNLI Stock Option (right to buy) Options Exercise $0 -27.8K -100% $0.00* 0 Jun 7, 2021 Common Stock 27.8K $18.92 Direct F6
transaction DNLI Stock Option (right to buy) Options Exercise $0 -27.2K -100% $0.00* 0 Jun 7, 2021 Common Stock 27.2K $19.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,074 restricted stock units.
F2 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F3 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.00 to $70.965 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.02 to $71.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 25% of the shares subject to the option vested on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.
F6 100% of the shares subject to the option were fully vested and exercisable.